April 13, 2026 — With Bristol Myers Squibb's blockbuster cancer immunotherapy Opdivo (nivolumab) facing patent expiration on May 2, 2026, the global biosimilar race is officially underway — and the implications for API suppliers, cell line developers, and contract biomanufacturing organizations are significant.
On January 22, 2026, Zydus Lifesciences launched the world's first nivolumab biosimilar in India after the Delhi High Court cleared the way, overturning a prior injunction sought by BMS. The product, marketed as ZRC-3276, is priced approximately 70% below Opdivo, dramatically expanding access to anti-PD-1 immunotherapy in one of the world's largest oncology markets.
Meanwhile, 17 biosimilar applications referencing Opdivo have been filed with the FDA in the United States, and multiple global developers — including Xbrane (partnered with Intas), Formycon, and several Chinese biopharmaceutical companies — are racing to be first to market in Western regulatory jurisdictions. With Opdivo generating over $10 billion in annual global revenue, the impending loss of exclusivity represents one of the largest patent cliffs in the biologics space since Humira.
The timing and geography of nivolumab patent expiries are complex, creating a staggered market entry opportunity for biosimilar developers worldwide.
In India, the core composition patent IN 340060 — covering the anti-PD-1 antibody sequence — expires on May 2, 2026. The Delhi High Court's January 2026 division bench ruling allowed Zydus to launch ahead of this date, finding that public interest considerations and the lack of product-to-claim mapping made continued injunction unjustified. Zydus has since indicated plans to be among the first to file a Biologics License Application (BLA) in the United States.
In the United States, BMS holds multiple patents on Opdivo, with key exclusivity extending through late 2028 for certain formulations and methods-of-use patents. Xbrane and its partner Intas have set a target launch of December 2028 in the US. In Europe, relevant patents expire around June 2030. This staggered timeline creates distinct commercial windows in different markets — and demand waves for suppliers.
Nivolumab is a fully human IgG4 monoclonal antibody produced via recombinant Chinese Hamster Ovary (CHO) cell culture. Unlike small-molecule generics, biosimilar manufacturing requires complex bioprocessing infrastructure, and the supply chain implications are correspondingly more involved.
Cell line development and banking. Each biosimilar developer needs a proprietary high-producing CHO cell line expressing the anti-PD-1 antibody. Cell line development providers — including contract research organizations specializing in clone selection, stability testing, and cell banking — are positioned to benefit as 17+ developers advance toward commercial manufacturing readiness.
Bioprocessing consumables and equipment. Large-scale monoclonal antibody production requires single-use bioreactor systems, chromatography resins, filtration membranes, and cell culture media. As multiple nivolumab biosimilar programs simultaneously move through process development and scale-up, aggregate demand for these consumables will increase. Suppliers of Protein A resins, in particular, should anticipate near-term order growth.
Analytical and quality testing services. Regulatory agencies worldwide require extensive comparability studies to demonstrate biosimilarity — including physicochemical characterization, biological activity assays, and immunogenicity assessment. Contract testing laboratories with capabilities in glycan analysis, surface plasmon resonance (SPR), and forced degradation studies are well positioned to capture this demand.
India's role in the nivolumab biosimilar race is particularly significant. Zydus Lifesciences' early launch has established a precedent for rapid biosimilar entry, and several other Indian manufacturers — including Biocon, Dr. Reddy's, and Intas — are developing their own anti-PD-1 programs.
However, Indian biosimilar developers face a critical supply chain constraint that is often overlooked: process solvents and petrochemical-derived raw materials. As detailed in a recent Pharmexcil advisory, the ongoing Strait of Hormuz disruption has created severe shortages of propylene, methanol, ammonia, and butane — key starting materials for solvents used in API and biologics purification. Solvent prices have risen approximately 50%, with potential for doubling.
For nivolumab biosimilar manufacturers, this means upstream procurement costs are rising at precisely the moment when capacity buildout is most aggressive. Suppliers of alternative purification solvents, single-use manufacturing technologies that reduce solvent dependency, and domestic Indian chemical producers are positioned to benefit from this supply chain reshuffling.
The competitive landscape for nivolumab biosimilars is unusually crowded, with implications for both developers and their suppliers.
Xbrane/Intas partnership represents one of the most advanced Western-market programs. Xbrane is accelerating development of Xdivane, its nivolumab biosimilar candidate, using its established microbial fermentation platform. Intas provides commercialization infrastructure across multiple markets.
Formycon has expanded its biosimilar portfolio through a collaboration with Lotus Pharmaceutical focused on the Asia-Pacific region. While the company's lead pembrolizumab biosimilar (FYB206) has drawn recent attention, its nivolumab program remains active.
Chinese developers — including Betta Pharma, which has filed for priority review of its nivolumab biosimilar — are targeting the domestic Chinese market first, where Opdivo faces price competition from locally developed checkpoint inhibitors including Junshi's toripalimab and Innovent's sintilimab. The NMPA's accelerated approval pathways for biosimilars are expected to bring multiple nivolumab products to the Chinese market by late 2026.
For suppliers, this competitive density is good news. Multiple developers means multiple procurement relationships, diversified demand across geographies, and reduced dependency on any single program's success or failure.
Companies across the pharmaceutical supply chain should consider the following actions as the nivolumab biosimilar wave unfolds:
1. Diversify solvent and raw material sourcing. With petrochemical supply disruptions affecting Indian manufacturers, suppliers with stable chemical supply chains — particularly in China, South Korea, and Southeast Asia — have an opportunity to capture market share from disrupted competitors.
2. Invest in biosimilar-grade analytical services. The regulatory bar for biosimilar approval is high. Laboratories that can demonstrate ICH Q5E-compliant comparability testing with rapid turnaround will be in strong demand as 17+ US filings move through review.
3. Build relationships with early-stage developers. Not all 17 FDA filers will reach market. But the cell line, analytical, and process development relationships established during clinical-stage development often translate into commercial supply contracts. Early engagement with mid-tier developers offers the highest long-term commercial potential.
4. Monitor the emerging Chinese biosimilar market. China's regulatory environment for biosimilars is maturing rapidly, and domestic developers will require local supply chain partners. Suppliers with established China operations — or willingness to build them — are positioned to capture this growing market.
The Opdivo patent cliff is not an isolated event. It is part of a broader pattern of blockbuster biologic patent expirations — including Kadcyla (ado-trastuzumab emtansine), Keytruda (pembrolizumab), and Eylea (aflibercept) — that will collectively reshape the biologics manufacturing supply chain over the next five years.
For API suppliers, bioprocessing equipment manufacturers, and contract testing organizations, the nivolumab biosimilar race is an early and high-profile test case. Those who establish credible positions in this market will be well positioned for the larger waves of biologic patent expiry that follow.
The May 2 patent date is just the beginning. The real commercial opportunity lies in the manufacturing infrastructure, analytical capabilities, and supply chain resilience that will power a generation of biosimilar medicines.
